Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
USANA Health Sciences, Inc.
USNA
NYSE·Consumer Defensive·Medical - Pharmaceuticals·Mkt cap $401.0M
$21.51
▼ -0.97%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$16.60 - $38.32
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 33.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Science-based product formulations with university research partnerships
- Established direct-to-consumer distribution network across 3 major regions
- Premium brand positioning supporting higher profit margins
- Diversified product portfolio addressing multiple health categories
- Proprietary digital tools and business support systems for associates
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Stable outlook
Expanding wellness market demand in Asia Pacific and emerging markets
Value
Attractively priced below Food & Beverage peer average
Momentum
Hot
+28.5% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying USNA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 20, 2026
MAY 5, 2026
Reported EPS of $0.61 vs $0.44 consensus (+38.6% surprise). Revenue of $250.0M vs $241.0M expected (+3.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+38.6%
Next: Apr 20, 2026
Revenue trend · last 8Q
—
—
-3%
+10%
+11%
+7%
+6%
+0%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 26
Q1 26
$212.9M
$200.2M
$213.6M
$249.5M
$235.8M
$213.7M
$226.2M
$250.2M
Margins · last 8Q
Gross
—
Operating
—
Profit
3.0%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
No analyst coverage on file for this stock yet.
vs Industry
How USNA stacks vs Medical - Pharmaceuticals
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related